Advertisement
Singapore markets closed

  • Straits Times Index

    3,313.48
    +8.49 (+0.26%)
     

  • Nikkei

    38,787.38
    -132.88 (-0.34%)
     

  • Hang Seng

    19,553.61
    +177.08 (+0.91%)
     

  • FTSE 100

    8,423.75
    -14.90 (-0.18%)
     

  • Bitcoin USD

    66,694.71
    +1,117.75 (+1.70%)
     

  • CMC Crypto 200

    1,357.97
    -15.88 (-1.16%)
     

  • S&P 500

    5,296.17
    -0.93 (-0.02%)
     

  • Dow

    39,887.33
    +17.95 (+0.05%)
     

  • Nasdaq

    16,691.43
    -6.89 (-0.04%)
     

  • Gold

    2,418.70
    +33.20 (+1.39%)
     

  • Crude Oil

    79.42
    +0.19 (+0.24%)
     

  • 10-Yr Bond

    4.3960
    +0.0190 (+0.43%)
     

  • FTSE Bursa Malaysia

    1,616.62
    +5.51 (+0.34%)
     

  • Jakarta Composite Index

    7,317.24
    +70.54 (+0.97%)
     

  • PSE Index

    6,618.69
    -9.51 (-0.14%)
     

AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference

Business Wire
·1-min read

MENLO PARK, Calif., January 30, 2024--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Details of the event is as follows:

Oppenheimer 34th Annual Healthcare Life Sciences Conference (virtual)

  • Eric Easom, Co-Founder, President and CEO will provide a corporate overview on Wednesday, February 14, 2024 at 10:40am ET.

ADVERTISEMENT

A webcast of the presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial candidate is epetraborole, which we are studying as a once-daily, oral treatment with a novel mechanism of action for patients with nontuberculous mycobacteria (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240130626235/en/

Contacts

COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
l.day@an2therapeutics.com

INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
ir@an2therapeutics.com